Meperidine (Demerol) Market, By Form (Tablet, Injection, and Syrup), By Application (Anesthesia, Cough Treatment, and Diarrhea Treatment), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East and Africa) -

Published In : Jun 2023

Code : CMI3816

Pages :150

Formats :

Excel and PDF

Industry : Pharmaceutical

Meperidine (Demerol) MarketSize and Trends

The global meperidine (Demerol) market is estimated to be valued at US$ 493.4 million in 2023 and is expected to exhibit a CAGR of 1.5 % during the forecast period (2023-2030).

Figure 1. Global Meperidine (Demerol) Market Share (%), by Form, 2023

Global Meperidine (Demerol) Market - Driver

Increasing prevalence of knee replacement therapies

Figure 2. Global Meperidine (Demerol) Market Value (US$ Million), by Region, 2023

Global Meperidine (Demerol) Market Cross Sectional Analysis:

Increasing facility expansion by key market players in Europe is expected to drive the growth of the application segment in this region. For instance, on December 2, 2022, Pfizer Inc., a U.S.-based pharmaceutical company, announced to expand its manufacturing sites at Puurs and Belgium. The company will spend US$ 1.2 billion for this expansion. Such facility expansions can increase production and drive the market growth.

Global Meperidine (Demerol) Market: Key Trends

Growth strategies like expansions can drive the growth of the global meperidine (Demerol) market over the forecast period. For instance, on December 5, 2022, Pfizer Inc., a U.S.-based pharmaceutical company announced that it will invest US$ 750 million to expand its facility in Michigan, U.S. The goal of the investment is to establish the facility as one of the most technologically advanced in the world and to ensure the uninterrupted supply of Pfizer medicines and vaccines.

Increasing research and development activities can drive the global meperidine (Demerol) market growth. For instance, according to an article published by Menopause Review on November 24, 2021, a total of 152 patients undergoing total or subtotal thyroidectomy were studied. Patients allocated to group A received a combination of intravenous (IV) paracetamol and intramuscular (IM) meperidine, patients in group B received a combination of IV paracetamol and IV parecoxib, while patients in group C received IV paracetamol monotherapy. It was found that the combinations of IV paracetamol with IM meperidine are superior to IV paracetamol monotherapy in achieving pain control in patients undergoing thyroid surgery.